10-QPeriod: Q3 FY2004

IDEXX LABORATORIES INC /DE Quarterly Report for Q3 Ended Sep 30, 2004

Filed November 8, 2004For Securities:IDXX

Summary

IDEXX Laboratories, Inc. reported strong financial performance for the nine months ended September 30, 2004, with total revenue increasing by 15% to $404.9 million compared to the prior year period. The Companion Animal Group (CAG) remains the primary revenue driver, showing a 17% increase in revenue. Profitability also saw significant improvement, with net income rising 33% to $61.4 million for the nine-month period. This growth was supported by increases in gross profit margin, which improved to 52% from 48% year-over-year, driven by operational efficiencies and favorable pricing within the CAG segment. The company also highlighted strategic acquisitions in Ohio and New York, along with planned acquisitions in Germany, Switzerland, and other European countries, indicating a continued focus on expansion. Despite robust growth, the company is managing inventory related to its NAVIGATOR® pharmaceutical product, which faces a smaller than anticipated market, and is negotiating with its supplier to mitigate potential inventory write-offs.

Key Highlights

  • 1Total revenue increased 15% to $404.9 million for the nine months ended September 30, 2004.
  • 2Net income grew 33% to $61.4 million for the nine-month period.
  • 3Gross profit margin improved to 52% from 48% year-over-year, indicating enhanced operational efficiency and pricing power.
  • 4The Companion Animal Group (CAG) continues to be the largest segment, with revenue up 17% year-over-year.
  • 5The company made strategic acquisitions of a veterinary reference laboratory and a production animal diagnostics company.
  • 6Significant planned acquisitions in Germany and Switzerland signal continued international expansion efforts.
  • 7The company is actively managing inventory risks related to its NAVIGATOR® pharmaceutical product.

Frequently Asked Questions

Revenue growth was primarily driven by increases in laboratory services, instrument consumables, and rapid assay products within the Companion Animal Group (CAG). The Water testing business and Food Diagnostics Group (FDG) also contributed positively, benefiting from increased sales volume and favorable currency exchange rates.

Profitability significantly improved, with net income increasing by 33% to $61.4 million for the nine months ended September 30, 2004. This was supported by a strong increase in gross profit margin to 52% from 48% in the prior year, driven by operational efficiencies, favorable pricing, and a reduction in warranty costs for certain products.

IDEXX Laboratories is actively pursuing growth through strategic acquisitions. They completed acquisitions of a veterinary reference laboratory in Ohio and a production animal diagnostics company in New York during the period. Furthermore, they announced plans for significant acquisitions in Germany, Switzerland, and other European countries, indicating a strong commitment to expanding their international presence.

The company noted challenges related to inventory for its NAVIGATOR® pharmaceutical product, as the market for it is smaller than initially anticipated. They are working with suppliers to mitigate potential inventory write-offs. Additionally, the company faces ongoing competition, regulatory scrutiny, and potential impacts from shifts in veterinary medical practices.